Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITIVA Protocol for AML Maintenance
NCT06256627Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2023
- Primary completion
- Mar 2025
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of interferon-alpha 1b, aldesleukin, thalidomide, venetoclax and azacitidine in acute myeloid leukemia (AML) (3 arms), sponsored by Henan Cancer Hospital. Primary endpoints: Negative MRD Conversion Rate at 2 years and Relapse Free Survival at 2 years. Started Jul 2023; status: recruiting.
02
Drugs
interferon-alpha 1baldesleukinthalidomidevenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06256627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256627.